

BOOTSTRAPPING & DISSOLUTION SIMILARITY: Q&A

Jiri Hofmann

BioBridges 2019


Prague, September 26-27, 2019



SIMILARITY: CLAIM OF EQUIVALENCE

Test	Reference
Test A	Test B
Biobatch	Biobatch
Pilot	Clinical
Strength 1	Strength 2
API 1	API 2
+Excipient	-Excipient
Site 1	Site 2

...






Type
(M)ANOVA
f1(2)
Bayesian
MD
Bootstrap
MSD
T^2 test
EDNE test
PCA

...

(M)ANOVA (multivariate) analysis of variance; f1(2) similarity factor; MD maximum deviation; MSD multivariate statistical distance; EDNE Euclidean distance of the nonstandardized expected (values); PCA principal component analysis




FIT FACTOR: MOORE & FLANNER

$$f_2 = 50 \log \left\{ \left[1 + \frac{1}{n} \sum_{i=1}^n (R_t - T_t)^2 \right]^{-0.5} \times 100 \right\}$$



SIMILARITY FACTOR: WHAT'S WRONG WITH YOU?

$$f_2 = 50 \log \left\{ \left[1 + \frac{1}{n} \sum_{i=1}^n (R_t - T_t)^2 \right]^{-0.5} \times 100 \right\}$$




STATISTICIANS: VIEW ON SIMILARITY FACTOR

(...) impossible to evaluate false positive or false negative (...). (...) too liberal in concluding similarity.

Liu et al. (1997). Drug Info J. 31: 1255-1271

(...) f_2 (...) series of monotone (...) transformations of the Euclidean distance, (...) procedure where neither the type I error rate nor power can be controlled and which really hurts a statistician's soul.

Hoffelder (2019). Biom J. 61(5): 1120-1137



EMA: REFLECTIONS

[6.3] **The f2 (...) unfavorable statistical properties (...), no (...) quantification of the risk to false positively conclude on similar dissolution is possible.**

[Answer:] (...) **is based only upon the (...) numerical value for f2 (point estimate ≥ 50). (...) uncertainty related to the f2 sampling distribution is not accounted for.**



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

- 1 23 March 2017
- 2 EMA/CHMP/138502/2017
- 3 Committee for Human Medicinal Products (CHMP)
- 4 Reflection paper on statistical
- 5 methodology for the comparative
- 6 assessment of quality attributes in
- 7 drug development.






EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 July 2018
EMA/810713/2017
Human Medicines Research and Development Support


Question and answer on the adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles

The aim (...) to a larger extent to emphasise the importance of confidence intervals to quantify the uncertainty around the point estimate of the chosen metric (...).

DISSOLUTION SIMULATION: $y = 100 \times (1 - e^{-kt})$



$f_2 > 50$




EMA Q&A: BOOTSTRAP

[Answer:] (...) **bootstrap methodology** could be used to derive confidence intervals for f2 (...), (...) **the preferred method over f2 and MD.** EMA/810713/2017

boot-strap /ˈbu:tstræp/ *noun* **IDM** pull / drag yourself up by your (own) bootstraps (*informal*) to improve your situation yourself, without help from other people

Oxford Advanced Learner's Dictionary of Current English (2000). Oxford University Press





Münchhausen

O. Herfurth pinx

Raspe (1785): Baron Munchausen's Narrative of his Marvellous Travels and Campaigns in Russia

BOOTSTRAPPING: PRINCIPLE

Unknown population of cannon balls




se_B bootstrap standard error
 se standard error of the mean

BOOTSTRAPPING DISSOLUTION: CI

90% bootstrap CI ⁽¹⁾		
Type	Lower	Upper
Normal	60.2217	66.9493
Percentile	59.8591	66.5973
Basic	60.5737	67.3119
BC	60.6481	67.4051
BCa	60.7555	67.5536
Bootstrap- $t^{(2)}$	60.5844	67.8099

⁽¹⁾R (v3.6.1); B0=10'000; ⁽²⁾B1=1'000; BC bias-corrected; BCa bias-corrected and accelerated.

Similarity (...) be declared if the CI for f_2 (...) entirely above 50.
EMA/810713/2017




BOOTSTRAPPING DISSOLUTION: ALL EASY?




90% bootstrap CI ⁽¹⁾ (data I)			90% bootstrap CI ⁽¹⁾ (data II)		
Type	Lower	Upper	Type	Lower	Upper
Normal	75.3720	105.6605	Normal	49.0571	65.8814
Percentile	62.7877	92.9877	Percentile	50.5090	67.4505
Basic	88.0448	118.2448	Basic	47.4880	64.4295
BC	87.4104	99.7090	BC	50.4077	67.3106
BCa	87.4081	99.7060	BCa	49.9249	66.4951
Bootstrap- <i>t</i> ⁽²⁾	87.9071	123.3391	Bootstrap- <i>t</i> ⁽²⁾	47.5351	66.7653
⁽¹⁾ R (v3.6.1); B0=10'000; ⁽²⁾ B1=1'000			⁽¹⁾ R (v3.6.1); B0=10'000; ⁽²⁾ B1=1'000		

BOOTSTRAPPING DISSOLUTION: ALPHA & POWER

Low %CV in dissolution




High %CV in dissolution



N=10'000
B=1'000

BOOTSTRAP IN PRACTICE: DL

[Major objection] **Biowaiver (...) may not be sufficiently supported (...). (...) 90% confidence interval of the f2 similarity factor calculated by bootstrapping (...). The output should include at least the number of bootstraps, the 5%, 50% (median) and 95% percentiles. Evidence that the statistical software has been validated should be provided as well.**




Percentiles (P)			
P	Shah et al.	DDSolver ⁽¹⁾	RE (%)
5%	53.01	53.53147	-0.97
95%	68.34	68.72088	-0.55

B=1'000; ⁽¹⁾Zhang et al. (2010)


Shah et al. (1998). Pharm Res 15(6): 889-896;
Zhang et al. (2010). AAPS J. 12(3): 263-267

BOOTSTRAP IN PRACTICE: ROUND 1




Percentiles	
5%	97.9487
50%	98.9720
95%	99.5367

B=50'000 in DDSolver



Percentiles	
5%	86.9786
50%	89.3210
95%	91.5900

B=50'000 in DDSolver



Percentiles	
5%	50.6544
50%	52.8409
95%	55.7312


B=50'000 in DDSolver

BOOTSTRAP IN PRACTICE: ROUND 2

90% bootstrap CI (Bootf2BCA) ⁽¹⁾		
Type	Lower	Upper
Percentile	50.6599	55.7327
Bootstrap- <i>t</i> ⁽²⁾	50.7184	56.6114
Normal	50.3144	55.4415
BCa	50.9257	56.3030
Basic	50.1124	55.1852

⁽¹⁾Mendyk et al., 2013; ⁽²⁾in-house R-code, R (v3.6.1); B0=50'000; B1=1'000

[Response to draft] (...) **to construct more versions of 90% confidence interval (...) to see if results regarding similarity are sufficiently robust.**



BOOTSTRAP IN PRACTICE: ROUND 3 & 4

[Response to draft] The assessor still finds unclear what is **difference between normal approximation method and basic bootstrap** (...). The Applicant is asked to fill in this information (...).

$$\hat{\theta} - b_R \mp v_R^{1/2} \cdot z^{(1-\alpha)}$$


Normal approximation

$$[2\hat{\theta} - \hat{\theta}^{*(1-\alpha)}, 2\hat{\theta} - \hat{\theta}^{*(\alpha)}]$$

Basic (backwards)

Davison & Hinkley (1997). Cambridge Press

[Response to final] (...) **the Applicant is asked to provide** (...) **software validation for individual approaches to see that obtained results can be considered as relevant.**



SUMMARY & QUESTIONS

- **f_2 : no control of type I error**
- **Bootstrap f_2 : confidence interval ... but harder to pass similarity criterion**
- **Equivalence margin: average 10%**
- **Dissolution in non-sink conditions**

Statistics vs. clinical relevance? Signals of problems available?

Type I error control? Which CI? Comparison to other methods? Applicable generally (EMA Q&A)?

Current margin already conservative? Maximum 10% (EMA Q&A) or average 10%?

API or product performance?

QUOTES: LIBRARY(FORTUNES)

```
> library(fortunes)
```

```
> fortunes::fortune(222)
```

Some people familiar with R describe it as a supercharged version of Microsoft's Excel spreadsheet software.

-- Ashlee Vance (in his article "Data Analysts Captivated by R's Power") The New York Times (January 2009)

```
> library(fortunes)
```

```
> fortunes::fortune(358)
```

The existence of a method is not a sufficient reason to use that method.

-- Jari Oksanen (about relative advantages of several multivariate analysis methods) R-SIG-Ecology (November 2013)